Search results for "Drug eluting beads"
showing 6 items of 6 documents
Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma
2015
Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…
Loading, release and stability of epirubicin-loaded drug-eluting beads.
2015
Purpose The aim of this study was to determine the loading efficiency, physico-chemical stability and release of epirubicin-loaded DC Bead™ (Biocompatibles UK Ltd, a BTG International group company) (bead size 70–150 µm (=DC Bead M1™) and 100–300 µm) after loading with epirubicin solution (2 mg/ml) or reconstituted powder formulation (25 mg/ml) and controlled storage. Methods DC Bead™ were loaded with 76 mg epirubicin solution (Epimedac™, Medac GmbH) or 75 mg epirubicin powder formulation (Farmorubicin™, Pharmacia Pfizer GmbH) per 2 ml of beads. Drug loading efficiency and stability were determined by measuring the epirubicin concentration in the excess solution after predetermined interval…
Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.
2012
Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media
2016
Purpose The aim of this study was to determine the compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media over a period of seven days when stored light protected under refrigerated conditions. Methods DC bead™ (2 ml) (Biocompatibles UK Ltd) of the bead size 70–150 µm ( = DC bead M1) or bead size 100–300 µm were loaded with 75 mg epirubicin powder formulation (Farmorubicin® dissolved in 3 ml water for injection to a concentration of 25 mg/ml) or 76 mg epirubicin injection solution (Epimedac® 2 mg/ml) within 2 h or 6 h, respectively. After removal of the excess solution, the epirubicin-loaded beads were mixed in polypropylene syringes with an equal volume (∼1.5 ml…
Stability of irinotecan-loaded drug eluting beads (DC BeadTM) used for transarterial chemoembolization
2009
Purpose. The aim of this study was to determine the loading efficiency, physicochemical stability, and release of irinotecan-loaded DC BeadsTM (bead size 100—300 μm, 300—500 μm) before and after mixing with nonionic contrast medium (Accupaque® 300, Imeron® 300, Ultravist ® 300) during a prolonged period of time (28 days) when stored at room temperature or refrigerated. Methods. DC Beads TM were loaded with 50 mg irinotecan (Campto®) per milliliter beads in a 2 h loading period. Drug loading efficiency and stability were determined by measuring the irinotecan concentration in the excess solution. A free-flowing in vitro elution method for a period of 2 h and phosphate buffered solution (PBS…
Transarteriālas ķīmijterapijas pielietošana aknu audzēju ārstēšanā
2016
Ievads: Transarteriāla ķīmijembolizācija ar medikamentus izdalošām mikrosfērām (DEB-TACE) ir audzēja apasiņojošo artēriju oklūzija digitālās subtrakcijas angiogrāfijas laikā, izmantojot mikrosfēras piesūcinātas ar ķīmijembolizācijas materiālu, kas pēc ievades pagarina saskares laiku starp audzēja šūnām un ķīmijterapijas medikamentiem. DEB-TACE tiek plaši pielietota hepatocelulārās karcinomas (HCC) paliatīvajā ārstēšanā, kad rezekcija vai ablācija nav iespējama. DEB-TACE tiek izmantota arī citu hipervaskulāru nerezicējamu aknu audzēju, piemēram, holangiokarcinomas, kolorektālu aknu metastāžu ārstēšanā. Optimāli kandidāti ārstēšanai ir Child-Pugh A un B klases pacienti ar lielu vai multifokāl…